Antidepressants one brother changes the lord! 9 billion market 6 over 500 million brands bright eyes

According to the WHO, there are more than 300 million people living with depression worldwideThe prevalence rate of depression in China is 2.1%, depression has become a global concern, but also promote the expansion of the market for antidepressantsAccording to Minet.com, sales of antidepressants at the end of Public Medical Institutions in China exceeded 9 billion yuan in 2019, up more than 10% year-on-yearIn recent years, with the continued efforts of domestic pharmaceutical companies such as Jingwei Pharmaceuticals, Huahai Pharmaceuticals, Kanghong Pharmaceuticals, Collon Pharmaceuticals and Haussen Pharmaceuticals, the market share growth rate of foreign pharmaceutical companies has slowed, and even some of them have declinedBrands TOP20, there are six brands more than 500 million yuan, of which, Lingbei oxalic acid Aesexi plantablet tablet sales fell by more than 20%, down nearly 200 million yuan, from the first place in 2018 to third, while Pfizer's hydrochloric acid sequoia, Yamatokyo Wei Pharma's oxalic acid Aescita planop stakes first and second placeBreaking 9 billion! The market for antidepressants has grown steadily, and foreign drug companies have been in the top threein recent years the sales of antidepressants in terminals in public medical institutions in China (units: 10,000 yuan)the "
HealthChina Action (2019-2030) released last July" proposed the implementation ofpsychology15 major initiatives, including health promotion, and further refine the goals, including reducing the prevalence of insomnia, the prevalence of anxiety disorders and the prevalence of depression by 2022 and 2030, and increasing the rate of treatment for depression by 30% and 80% on the existing basisIn addition, it is proposed to integrate social resources and set up mental health counseling centers for minors at the municipal and county levelsIn recent years, china's urban publichospitals , county-level public hospitals, urban community centers and township hospitals (china's public medical institutions) terminal anti-depressive drug market has grown rapidly, with sales exceeding 9 billion yuan in 2019, according to Minnet.com the pattern of terminal antidepressants in public medical institutions in China in recent years
　　In terms of channel patterns, urban public hospitals have been declining in recent years, with market share falling below 80% in 2019, while county-level public hospitals, urban community centers and township hospitals have grown steadily 　　In 2019, the competitive pattern of China's public medical institutions terminal antidepressants enterprises from the competitive pattern of enterprises, Pfizer, Lingbei, Lilly three foreign pharmaceutical companies ranked in the top three positions, the market share in 2019 is more than 10%, Pfizer is the first In recent years, with the continued efforts of domestic pharmaceutical companies such as Jingwei Pharmaceuticals, Huahai Pharmaceuticals, Kanghong Pharmaceuticals, Collon Pharmaceuticals and Haussen Pharmaceuticals, the market share growth rate of foreign pharmaceutical companies has slowed, and even some of them have declined 　　Brand TOP20 out! "Antidepressant one brother" change, Howson, Collum, Huahai .. Power China's public medical institutions terminal antidepressant brand TOP20 (units: 10,000 yuan) brand TOP10, Pfizer, Lingbei, Lilly and other foreign pharmaceutical companies occupy 4 seats; In terms of sales, six brands exceeded 500 million yuan, of which lingbei oxalic acid Aisiplana tablet sales fell the most, down nearly 200 million yuan year-on-year, from the first to third place in 2018, while Pfizer's hydrochloric acid schaeuble, Yamatokyo Wei Pharma's oxachloric acid Acesieplanaplan tablets took first and second place Jingwei, Collum, Huahai and other domestic pharmaceutical companies to grab 2billion of large varieties
in recent years, China's public medical institutions terminal Aisi sipriated tablet sales (units: 10,000 yuan) oxalic acid Aisisiplan tablets jointly developed by H Lundbeck A/S and Allergan, mainly used to treat depression, in August 2002 the drug was approved by the FDA for sale The U.S oxalic acid Aescita plan tablet manufacturers are mainly Lupin, Torrent, Cipla, etc., the product was approved for listing in China in 2006 According to the data of Minnet According to the data, in 2019 the sales of aixiplan tablets at the end of Public Medical Institutions in China are nearly 2 billion yuan, and the main production enterprises are Yamasto Wei Pharmaceuticals, Lingbei, Sichuan Collum Pharmaceuticals, Hunan Dongting Pharmaceuticals, Jinhua Kangenbei Biopharmaceuticals, Jilin West Point Pharmaceuticals In November 2019, Zhejiang Huahai Pharmaceuticals' oxalic acid Aisi sipriate tablets were approved for listing in imitation 4 categories, as if approved by consistency evaluation 　　It is worth mentioning that in 2018 Lingbei oxalic acid aisipriator tablets with a growth rate of more than 30% to occupy the first antidepressant brand, market share of up to 45.68 percent, 2019 sales significantly declined, market share of only 35.27 percent In addition, sales of Oxalic Aisi-Si-Panplan tablets from Tokyo-Tokyo Wei Pharmaceuticals exceeded 700 million yuan in 2019, while sales of Sichuan Collum Pharmaceuticals, Hunan Dongting Pharmaceuticals and Jinhua Kangenbei Biopharmaceuticals grew by more than 30% growth of 98% ! Howson won the first imitation of "kill into" the top ten in recent years, China's public medical institutions terminal agomeratin tablet sales (units: 10,000 yuan) agomelatin for adult depression treatment, by the French Schweia original study Howson Pharmaceuticals' Agomeratin tablets (commodity name: Amenin) are the first generic drug of China's Agomeratin, which went on sale in 2014 and is the only agomylatin generic drug approved for sale in the country According to Minet.com, a number of agometine tablets in China's public medical institutions, sales of terminals grew rapidly, exceeding 200 million yuan in 2019, up 98.24% YoY, with strong growth rate "killing" anti-depressive drugs top 10 　　According to the data, sanofi China and Schvia China reached an exclusive strategic cooperation agreement last September on the antidepressant Agomeratin tablets developed by Sweetta (product name: dimension new), and Sanofi China will be fully responsible for the marketing and promotion of the drug after it goes on sale In April, According to Sanofi China, Dimension new prescriptions were issued simultaneously in Beijing and Xi'an 　　10
antidepressants, 5 only 1
antidepressants
as of June 15, 10 products of antidepressants passed (including pass-through) consistency evaluation, including hydrochloric acid vesilate tablets, hydrochloric acid Losie Only 1 enterprises have of the five products, such as tin-intestinal capsules, hydrobromic acid citalopram capsules, and the most evaluated enterprises of oxalic acid Aisixiplan tablets, involving 5 enterprises such as SanTokyo Wei Pharmaceutical, Sichuan Collum Pharmaceuticals, Zhejiang Huahai Pharmaceuticals, etc Source: Minnet Database, Announcement sed